The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
 
Kohei Shitara
Honoraria - Chugai Pharma; Takeda
Consulting or Advisory Role - Bayer; Chugai Pharma; Lilly Japan
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Yasuhide Yamada
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Dainippon Sumitomo Pharma; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Merck Serono; Novartis; Otsuka; Taiho Pharmaceutical
 
Kiyotaka Yoh
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bayer; Lilly; Novartis; Takeda
 
Yoichi Naito
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Noboru Yamamoto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Eisai (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Anja von Heydebreck
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Hiroyuki Achiwa
Employment - Merck Serono
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)